PT  - JOURNAL ARTICLE
AU  - Shreena Umit Patel
AU  - Ruhaid Khurram
AU  - Anjali Lakhani
AU  - Bernadine Quirk
TI  - Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1
AID  - 10.1136/bcr-2021-242956
DP  - 2021 Apr 01
TA  - BMJ Case Reports
PG  - e242956
VI  - 14
IP  - 4
4099  - http://casereports.bmj.com/content/14/4/e242956.short
4100  - http://casereports.bmj.com/content/14/4/e242956.full
SO  - BMJ Case Reports2021 Apr 01; 14
AB  - Prevention strategies for COVID-19 transmission are at the forefront of healthcare paradigms worldwide, the main emphasis of which is vaccination. We present an interesting case of a 37-year-old man who, 3 weeks following his first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1, presented to hospital with a rapidly progressive ascending muscle weakness and back pain in the absence of any other triggers. He also had a negative COVID-19 swab during admission. A diagnosis of Guillain-Barre syndrome was confirmed by correlating the clinical features with cerebrospinal fluid analysis, nerve conduction studies and MRI of the brain and whole spine. The patient received treatment with 5 days of intravenous immunoglobulin and did not require any respiratory support. He was also regularly reviewed by a multidisciplinary team consisting of neurologists, speech and language therapists, and physiotherapists and is on the course to a recovery.